Description

Simple

A medication used to treat high levels of uric acid after chemotherapy for some cancers.

Clinical

A recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma.

Overview

Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.

Pharmacology

Indication

For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)

Pharmacodynamic

Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced... Read more

Mechanism of action

Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

110 to 127 mL/kg [pediatric patients]75.8 to 138 mL/kg [adult patients]

Clearance

Information currently not available.

Half life

18 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Methemoglobinemia
      • Drugbank Id: DBCOND0001602
  • Patient Conditions Associated With:
      • Name: Glucose-6-Phosphate Dehydrogenase Deficiency
      • Drugbank Id: DBCOND0069342
  • Regions: US
  • Patient Conditions:
      • Name: Hemolysis
      • Drugbank Id: DBCOND0004960
  • Patient Conditions Associated With:
      • Name: Glucose-6-Phosphate Dehydrogenase Deficiency
      • Drugbank Id: DBCOND0069342
  • Hypersensitivity:
    • true
  • Regions: US
  • Regions: US
  • Patient Conditions:
      • Name: Glucose-6-Phosphate Dehydrogenase Deficiency
      • Drugbank Id: DBCOND0069342

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Rasburicase
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Bendroflumethiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Bendroflumethiazide.
Benzthiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Benzthiazide.
Chlorothiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Chlorothiazide.
Cyclopenthiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Cyclopenthiazide.
Cyclothiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Cyclothiazide.
Hydrochlorothiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Hydrochlorothiazide.
Hydroflumethiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Hydroflumethiazide.
Mebutizide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Mebutizide.
Methyclothiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Methyclothiazide.
Polythiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Polythiazide.
Trichlormethiazide
The therapeutic efficacy of Rasburicase can be decreased when used in combination with Trichlormethiazide.
2 References
  1. 1 . Collings I, Watier Y, Giffard M, Dagogo S, Kahn R, Bonnete F, Wright JP, Fitch AN, Margiolaki I: Polymorphism of microcrystalline urate oxidase from Aspergillus flavus. Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):539-48. doi: 10.1107/S0907444910005354. Epub 2010 Apr 21.PubMed: 20445229
  2. 2 . Giraldez M, Puto K: A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol. 2010 Aug;85(2):177-9. doi: 10.1111/j.1600-0609.2010.01457.x. Epub 2010 Apr 12.PubMed: 20394650